AZD5363 is a potent Akt inhibitor for Akt1, Akt2 and Akt3 with IC50 of 3 nM, 8 nM and 8 nM, respectively.
|Source||Cancer Biol Ther (2018). Figure 3. AZD5363|
|Cell Lines||HEK293T cells|
|Incubation Time||24 h|
|Results||Proliferation of homozygous H2189Y mutant cells was significantly inhibited by the mTOR inhibitor everolimus (P =0.018), the PI3K inhibitor LY294002 (P D 0.016), and the AKT inhibitors AZD5363 (P = 0.009) and MK-2206 (P = 0.003). The PI3K inhibitor Wortmannin had no significant effect on proliferation in these five cell lines|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Solubility||DMSO 60 mg/mL|
|Related Akt Products|
Miransertib, also known as ARQ 092, is an oral activie, potent and selective AKT inhibitor with IC50 values: 5.0 nM (AKT1); 4.5 nM (AKT2); 16 nM (AKT3).
GSK2141795 is a potent and selective pan-Akt inhibitor with IC50 values of 180 nM for Akt1, 328 nM for Akt2, and 38 nM for Akt3 respectively (Clinical phase 1).
GDC-0068(RG 7440) 2Hcl is a highly selective pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 5 nM/18 nM/8 nM, 620-fold selectivity over PKA.
Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2.
SC79 is an inhibitor of Akt-PH domain translocation and a specific Akt activator used to enhance Akt activity in various conditions.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.